Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Psoriasis
Findings from Case Western Reserve University in psoriasis reported
November 9th, 2008
According to recent research from the United States, "Alefacept is the first biologic agent approved by the US Food and Drug Administration for the treatment of psoriasis." "To date, more than 1000 patients with moderate to severe psoriasis have been enrolled in phase III clinical trials of alefacept. More than 30% of patients treated with 2 courses of alefacept reached a Physician's Global Assessment of clear to almost clear, and approximately 40% and 70% of patients achieved a Psoriasis Area Severity Index score of 75 and 50 after the same regimen," wrote H. Sugiyama and colleagues, Case Western Reserve University. The researchers concluded:...
Source: Medical Letter on the CDC & FDA (2008-11-09)
|
